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Abstract
Background: Breast cancer in the elderly may follow a less aggressive course. There are data
suggesting that radiotherapy (RT) following breast conserving surgery (BCS) for invasive carcinoma
may not be necessary in some elderly patients. The addition of RT to surgery might constitute an
imposition to such patients due to age-related factors. The aim of this study was to assess the
efficacy of BCS without adjuvant RT in this group of patients.
Patients and methods: A retrospective review of 92 elderly (median age 75 years; range: 70 –
87 years) patients (analysed as 93 'patients' due to one patient having bilateral cancers) managed in
a dedicated breast clinic and who underwent BCS for invasive carcinoma was carried out. Eighty-
three patients did not receive postoperative RT to the breast (no-RT group) whereas the remaining
10 had RT (RT-group).
Results: The median age in this group was 75 (range 70 – 87) years. The mean tumour size was
18 mm with a median follow-up of 37 (range 6 – 142) months. In the no RT group, adjuvant
endocrine therapy with tamoxifen was given to 40/53 patients. No patients in the oestrogen
receptor (ER) negative group received tamoxifen. The local recurrence (LR) rate in this group was
8.4% (2.4% per year, n = 7/83), with median time to LR of 17 months. In this no-RT group LR was
correlated to ER status (2/53 ER+, 5/26ER-, p = 0.024) and margins of excision (n = 1/54 >5 mm,
2/17 1–5 mm, 4/12 <1 mm, p = 0.001). Within the ER positive group the LR rate was 0.92% per
annum (0.62% per annum in patients treated with adjuvant tamoxifen, regardless of margin status).
Breast cancer specific survival was correlated to histological grade (p < 0.05) and ER status (p <
0.05).
Conclusion: It would appear that omission of RT following successful BCS in elderly patients with
ER positive tumours receiving adjuvant tamoxifen may be acceptable. The LR rate as shown in this
retrospective study is highly comparable to that of younger patients treated by conventional
therapy. This concept is now being evaluated prospectively following a change in treatment
practice.
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The majority of breast cancers are diagnosed in women >
65 years of age, although research efforts are, for the most
part, focused on younger patients. Treatment of breast
cancer in the elderly is controversial and is often extrapo-
lated from their younger counterparts [1]. However, it is
evident that there is a huge variation in treatment patterns
due to patient age [2-6]. A greater knowledge of breast
cancer behaviour and optimal treatment in the elderly is
urgently needed. It has been suggested that breast cancer
may follow a less aggressive course in older women. This
may partly be due to the more frequent detection of breast
cancer in earlier stages in this group compared to younger
patients where the breast gland is denser. Some data sug-
gest that elderly breast cancers have inherently different
biological features and clinical behaviour; for instance,
breast cancer in the elderly tends very often to be oestro-
gen receptor (ER) positive [7]. However, further studies
are required to evaluate the benefit from adjuvant treat-
ments in this group of patients.
Adjuvant radiotherapy to the breast after breast conserv-
ing surgery (BCS) is the mainstay of treatment to achieve
local control in patients with invasive carcinoma. How-
ever, the benefit from any adjuvant treatment is directly
related to the patients overall co-morbidity and life
expectancy. The addition of radiotherapy may constitute
an imposition to such patients due to its side effects and
other age-related factors such as inconvenience.
This retrospective analysis aimed to address the efficacy of
BCS without adjuvant radiotherapy in the elderly popula-
tion.
Patients and methods
Since 1973 all elderly (> 70 years) patients with early pri-
mary breast cancer (< 5 cm) in Nottingham have been
managed in a dedicated Elderly Primary Breast Cancer
Clinic according to a defined set of treatment guidelines.
During the period of 1989 – 2000, patients with invasive
breast carcinoma < 3 cm clinically were given the choice
between BCS and mastectomy. Those who had ER positive
cancer were also given the option of receiving primary
endocrine therapy. Searching the patient database identi-
fied 92 patients with primary invasive breast carcinoma
over the age of 70 during this period who were treated
with BCS as the primary treatment. These patients either
had ER positive tumours but did not receive primary
endocrine therapy, or had ER negative tumours. Postoper-
ative intact breast irradiation following BCS was not rou-
tine for the elderly patients before 1999.
Local recurrence was defined as histologically proven ipsi-
lateral recurrence of breast carcinoma within the treated
breast following previous BCS. It was usually located in
close proximity to the location of the previously treated
primary carcinoma, otherwise histology review to confirm
morphological similarity was required. Tumour with a
Histochemical score (H-score) of = 50 by standard immu-
nohistochemistry studies was deemed ER positive.
The medical records of the 92 patients were reviewed in
order to identify demographic and follow up details,
tumour characteristics, local, regional and systemic recur-
rence rates and overall survival. There was one patient
with bilateral breast cancer at presentation and this
patient was included in the database twice (one entry for
each cancer) for the purposes of the statistical analysis in
respect of local recurrence (total number of cancers, 93).
SPSS for windows (version 11.0) was used to analyse the
database. Kaplan-Meier tables were used to identify corre-
lations between local recurrence, regional recurrence, sys-
temic recurrence and overall survival and tumour
characteristics and treatment parameters.
Results
A total of 82 patients (83 cancers) did not receive adjuvant
radiotherapy to the breast (group A). Ten patients received
adjuvant radiotherapy to the breast (group B). The
median age was 75 (range: 70 – 87) years. There were 13,
41 and 39 cancers of Grade 1, 2, and 3, respectively.
Group A: There were seven (8.4%) local recurrences with
a median follow up of 37 (range 6 – 142) months, trans-
lating to an annual recurrence rate of 2.4% per annum.
The median time to local recurrence was 17 (range 3 – 96)
months. Group B: There were no local recurrences in this
group observed during the same period. However, the dif-
ference in the local recurrence rate between the two
groups was not statistically significant. This was mainly
due to the small size of the group, during the period of the
study because adjuvant radiotherapy to the breast was
implemented after the year 1999 in this age group. For the
purpose of the study, group B has been excluded from fur-
ther statistical analysis.
Group A: Fifty-three cancers were ER positive and 26 were
ER negative. ER status was not recorded in four patients.
Forty of the 53 ER positive patients were treated with adju-
vant tamoxifen. The median size of the cancers was 19
mm (range 2 mm – 40 mm). Seventeen patients had had
axillary surgery and of those, 11 were node negative.
Local recurrence in Group A significantly correlated with
margins of excision (p < 0.001) (Figure 1a); there were 4/
12, 2/17 and 1/54 local recurrences corresponding to mar-
gin status <1 mm, 1–5 mm and >5 mm, respectively. Local
recurrence also correlated with ER status (p = 0.024) (Fig-
ure 1b) and size of tumour (p < 0.001). There were 2/53Page 2 of 5
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in the ER negative group. Within the ER positive group the
local recurrence rate was 0.92% per annum (p.a.) (0.62%
p.a. in patients treated with adjuvant tamoxifen,
(1.78%p.a. when no adjuvant tamoxifen was given)
(Table 1). There were 1/8, 1/35, 4/39 and 1/1 local recur-
rences corresponding to tumour size categories of <10
mm, 11–20 mm, 21–30 mm and 31–40 mm in size,
respectively.
Local recurrence did not correlate with lympho-vascular
invasion (p = 0.7) or tumour grade (p = 0.5). However,
histological grade correlated with regional (i.e. ipsilateral
axillary lymph node) recurrence (p < 0.05) and overall
survival (p < 0.005) (Figure 2). Survival also correlated
with ER status (p < 0.01) (Figure 2).
Discussion
Pooled data from individual studies or meta-analysis have
shown that omission of radiotherapy after BCS generally
produces adverse effects mainly on local recurrence and to
some degree on survival [8-12]. The use of tamoxifen
alone aiming to avoid radiotherapy has not been shown
to produce satisfactory local control when 769 patients
older than 50 years were investigated [13]. On the other
hand, there are little data on which to assess the precise
role of radiotherapy after BCS in the management of eld-
erly patients with primary breast cancer. Data suggest that
local recurrence rates are higher in younger women, with
trials showing that they diminish with increasing age,
especially when tamoxifen is given [14-18]; intact breast
irradiation may not therefore be required to achieve simi-
lar local control in the elderly patients.
Before 1999, elderly patients (> 70 years) in Nottingham
with primary breast cancer < 3 cm were given a choice
between BCS and mastectomy, regardless of ER status.
Patients were not given breast irradiation following suc-
cessful wide local excision and this was the main group of
patients studied in this paper (group A). Results show an
excellent local control in the group of patients who had
achieved adequate margins of excision (>5 mm at radial
A) Patients who had no radiotherapy (RT) following breast conserving surgery – Relationship between local recurrence (LR) and margins of excisionFigure 1
A) Patients who had no radiotherapy (RT) following breast conserving surgery – Relationship between local recurrence (LR) 
and margins of excision. B). Patients who had no radiotherapy (RT) following breast conserving surgery – Relationship between 
local recurrence (LR) and oestrogen receptor (ER) status.
Table 1: Within the oestrogen receptor (ER) positive group, local recurrence (LR) was less than 1% per annum in patients treated with 
adjuvant tamoxifen.
N LR(+) LR(-)
Adjvuant endocrine 1 (2.5%) 39 40
No adjuvant 1 (7.7%) 12 13
2 52 53
p = 0.4 (non-significant)Page 3 of 5
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adjuvant tamoxifen (0.62% local recurrence rate per
annum). This 0.62% per annum rate of local recurrence
was noted regardless of margin width and tumour size,
although these features were shown in this study to have
correlation with local control in this group of patients. It
would therefore be expected that local recurrence in the
group of patients over the age of 70, treated by BCS and
receiving tamoxifen for an ER positive tumour, would be
even lower if the tumour was small (e.g. < 3 cm) and an
adequate radial margin of excision (e.g. > 5 mm) was
achieved. This is highly comparable to, or even better
than, the local recurrence rate in younger patients who are
treated with BCS followed by radiotherapy.
Similar results have been reported in other centres with
both retrospective and prospective studies, showing rea-
sonable local control in patients who received tamoxifen
but no radiotherapy following lumpectomy [19,20]. In
the retrospective study of Benhaim DI et al., [19] the
results were better in lumpectomy with tamoxifen arm
compared to standard treatment while in prospective
study of Hughes KS et al., [20] there was no difference in
5 year overall survival though the local recurrence at 5 year
was 3% higher. It would appear that omission of radio-
therapy following BCS in elderly patients who are receiv-
ing adjuvant tamoxifen may be acceptable. We have since
changed our treatment policy; elderly patients who have
had successful wide local excision for an ER positive inva-
sive breast carcinoma (with a circumferential margin = 5
mm) and who require adjuvant tamoxifen receive no radi-
otherapy to the intact breast. Patients with ER negative
tumours are now routinely given radiotherapy. Results are
being monitored and will be reported in the future.
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